Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151688 | 0.95 | CA1 (0.59) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1710732 | 0.92 | CA2 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL10803892 | 0.92 | CA1 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1710998 | 0.92 | CA2 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1710506 | 0.91 | CA2 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1710503 | 0.91 | CA2 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1962748 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL12955914 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8982625 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL31272586 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144788-B2 | Visual cycle modulators | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | NATIONAL SCIENCE FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022165427-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220175700-A1 | VISUAL CYCLE MODULATORS | UNIV CASE WESTERN RESERVE (US) | 2022-06-09 | — | — | US | disclosed |
| US-11253489-B2 | Visual cycle modulators | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20220175700-A1 | VISUAL CYCLE MODULATORS | ALDH1A2, UACA, NR2E3 | CA1 3279/4885CA2 1626/4885CA12 3251/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | UACA, CRYZ, MAPT | CA1 1005/4885CA2 130/4885CA12 155/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CA1 4856/4885CA2 3656/4885CA12 4648/4885 |
| US-12144788-B2 | Visual cycle modulators | ALDH1A2, UACA, NR2E3 | CA1 3279/4885CA2 1626/4885CA12 3251/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | CA1 4504/4885CA2 1943/4885CA12 2817/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CA1 4852/4885CA2 3650/4885CA12 4643/4885 |
| US-11253489-B2 | Visual cycle modulators | ALDH1A2, UACA, NR2E3 | CA1 3279/4885CA2 1626/4885CA12 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.